Immunologic Research

, Volume 43, Issue 1–3, pp 77–84 | Cite as

Advances in treatment for chronic granulomatous disease



Chronic granulomatous disease (CGD) is a rare congenital disorder resulting from a failure of neutrophils to produce oxidases. Patients are therefore prone to recurrent infections from various organisms including fungi and atypical bacteria. The mortality in patients with the X-linked form of CGD, the most common type, ranges from 3% to 5% per year and although management of infections has improved with advances in antimicrobial therapies, better methods are needed to be able to cure these patients. Peripheral blood stem cell or bone marrow transplantation, while curative, is not widely used due to the episodic nature of the infections and the belief by many that conservative management is preferable to the risks of transplantation. Still, as will be discussed, improvements in the field are making allogenic transplantation more desirable and tilting the risk benefit ratio in favor of this modality. Additionally, gene therapy, which has been a long touted method to cure CGD, has within the last 5–10 years become more and more of a reality and may be realized by the end of this decade.


Chronic granulomatous disease Gene therapy Allogeneic transplantation Autoimmune complications Antibiotic prophylaxis Interferon gamma 


  1. 1.
    Ahlin A, et al. Prevalence, genetics and clinical presentation of chronic granulomatous disease in Sweden. Acta Paediatr. 1995;84(12):1386–94.PubMedCrossRefGoogle Scholar
  2. 2.
    Winkelstein JA, et al. Chronic granulomatous disease. Report on a national registry of 368 patients. Medicine (Baltimore). 2000;79(3):155–69.CrossRefGoogle Scholar
  3. 3.
    Roos D. The genetic basis of chronic granulomatous disease. Immunol Rev. 1994;138:121–57.PubMedCrossRefGoogle Scholar
  4. 4.
    Segal BH, et al. Genetic, biochemical, and clinical features of chronic granulomatous disease. Medicine (Baltimore). 2000;79(3):170–200.CrossRefGoogle Scholar
  5. 5.
    De Ravin SS, et al. Sarcoidosis in chronic granulomatous disease. Pediatrics. 2006;117(3):e590–5.PubMedCrossRefGoogle Scholar
  6. 6.
    Strate M, Brandrup F, Wang P. Discoid lupus erythematosus-like skin lesions in a patient with autosomal recessive chronic granulomatous disease. Clin Genet. 1986;30(3):184–90.PubMedGoogle Scholar
  7. 7.
    Manzi S, et al. Systemic lupus erythematosus in a boy with chronic granulomatous disease: case report and review of the literature. Arthritis Rheum. 1991;34(1):101–5.PubMedCrossRefGoogle Scholar
  8. 8.
    Lee BW, Yap HK. Polyarthritis resembling juvenile rheumatoid arthritis in a girl with chronic granulomatous disease. Arthritis Rheum. 1994;37(5):773–6.PubMedCrossRefGoogle Scholar
  9. 9.
    Ortiz-Romero PL, et al. Lupus like lesions in a patient with X-linked chronic granulomatous disease and recombinant X chromosome. Dermatology. 1997;195(3):280–3.PubMedCrossRefGoogle Scholar
  10. 10.
    Bendhack ML, et al. Chronic granulomatous disease masquerading as a bladder tumor: a potential source of diagnostic error. Eur Urol. 1997;32(3):380–4.PubMedGoogle Scholar
  11. 11.
    al-Tawil YS, et al. Steroid-responsive esophageal obstruction in a child with chronic granulomatous disease (CGD). J Pediatr Gastroenterol Nutr. 1996;23(2):182–5.PubMedCrossRefGoogle Scholar
  12. 12.
    Lindahl JA, Williams FH, Newman SL. Small bowel obstruction in chronic granulomatous disease. J Pediatr Gastroenterol Nutr. 1984;3(4):637–40.PubMedCrossRefGoogle Scholar
  13. 13.
    Johnson FE, et al. Gastric outlet obstruction due to X-linked chronic granulomatous disease. Surgery. 1975;78(2):217–23.PubMedGoogle Scholar
  14. 14.
    Gallin JI, et al. Itraconazole to prevent fungal infections in chronic granulomatous disease. N Engl J Med. 2003;348(24):2416–22.PubMedCrossRefGoogle Scholar
  15. 15.
    Weening RS, Leitz GJ, Seger RA. Recombinant human interferon-gamma in patients with chronic granulomatous disease—European follow up study. Eur J Pediatr. 1995;154(4):295–8.PubMedGoogle Scholar
  16. 16.
    Marciano BE, et al. Long-term interferon-gamma therapy for patients with chronic granulomatous disease. Clin Infect Dis. 2004;39(5):692–9.PubMedCrossRefGoogle Scholar
  17. 17.
    Ohga S, et al. Interferon-gamma therapy for infection control in chronic granulomatous disease. Acta Paediatr Jpn. 1995;37(3):315–20.PubMedGoogle Scholar
  18. 18.
    Woodman RC, et al. Prolonged recombinant interferon-gamma therapy in chronic granulomatous disease: evidence against enhanced neutrophil oxidase activity. Blood. 1992;79(6):1558–62.PubMedGoogle Scholar
  19. 19.
    The International Chronic Granulomatous Disease Cooperative Study Group. A controlled trial of interferon gamma to prevent infection in chronic granulomatous disease. N Engl J Med. 1991;324(8):509–16.Google Scholar
  20. 20.
    Tisdale JF, et al. Ex vivo expansion of genetically marked rhesus peripheral blood progenitor cells results in diminished long-term repopulating ability. Blood. 1998;92(4):1131–41.PubMedGoogle Scholar
  21. 21.
    Kiem HP, et al. Improved gene transfer into baboon marrow repopulating cells using recombinant human fibronectin fragment CH-296 in combination with interleukin-6, stem cell factor, FLT-3 ligand, and megakaryocyte growth and development factor. Blood. 1998;92(6):1878–86.PubMedGoogle Scholar
  22. 22.
    Cavazzana-Calvo M, et al. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease [see comments]. Science. 2000;288(5466):669–72.PubMedCrossRefGoogle Scholar
  23. 23.
    Hacein-Bey-Abina S, et al. A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N Engl J Med. 2003;348(3):255–6.PubMedCrossRefGoogle Scholar
  24. 24.
    Malech HL, et al. Extended production of oxidase normal neutrophils in X-linked chronic granulomatous disease (CGD) following gene therapy with gp91phos transduced CD34+ cells. Blood. 1998;92(10(Suppl)):690a.Google Scholar
  25. 25.
    Malech HL, et al. Prolonged production of NADPH oxidase-corrected granulocytes after gene therapy of chronic granulomatous disease. Proc Natl Acad Sci USA. 1997;94(22):12133–8.PubMedCrossRefGoogle Scholar
  26. 26.
    Ott MG, et al. Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nat Med. 2006;12(4):401–9.PubMedCrossRefGoogle Scholar
  27. 27.
    Calmels B, et al. Recurrent retroviral vector integration at the MDS1-EVI1 locus in non-human primate hematopoietic cells. Blood. 2005;106(7):2530–3.PubMedCrossRefGoogle Scholar
  28. 28.
    Roesler J, et al. Third-generation, self-inactivating gp91(phox) lentivector corrects the oxidase defect in NOD/SCID mouse-repopulating peripheral blood-mobilized CD34+ cells from patients with X-linked chronic granulomatous disease. Blood. 2002;100(13):4381–90.PubMedCrossRefGoogle Scholar
  29. 29.
    Brenner S, et al. Concentrated RD114-pseudotyped MFGS-gp91phox vector achieves high levels of functional correction of the chronic granulomatous disease oxidase defect in NOD/SCID/{beta}2-microglobulin−/− repopulating mobilized human peripheral blood CD34+ cells. Blood. 2003;102(8):2789–97.PubMedCrossRefGoogle Scholar
  30. 30.
    Horwitz ME, et al. Treatment of chronic granulomatous disease with nonmyeloablative conditioning and a T-cell-depleted hematopoietic allograft. N Engl J Med. 2001;344(12):881–8.PubMedCrossRefGoogle Scholar
  31. 31.
    Seger RA, et al. Treatment of chronic granulomatous disease with myeloablative conditioning and an unmodified hemopoietic allograft: a survey of the European experience, 1985–2000. Blood. 2002;100(13):4344–50.PubMedCrossRefGoogle Scholar
  32. 32.
    Bhattacharya A, et al. Successful umbilical cord blood stem cell transplantation for chronic granulomatous disease. Bone Marrow Transplant. 2003;31(5):403–5.PubMedCrossRefGoogle Scholar
  33. 33.
    Watanabe C, et al. Successful unrelated bone marrow transplantation for a patient with chronic granulomatous disease and associated resistant pneumonitis and Aspergillus osteomyelitis. Bone Marrow Transplant. 2001;28(1):83–7.PubMedCrossRefGoogle Scholar
  34. 34.
    Ozsahin H, et al. Successful treatment of invasive aspergillosis in chronic granulomatous disease by bone marrow transplantation, granulocyte colony-stimulating factor-mobilized granulocytes, and liposomal amphotericin-B. Blood. 1998;92(8):2719–24.PubMedGoogle Scholar
  35. 35.
    Kobayashi S, et al. Clinical features and prognoses of 23 patients with chronic granulomatous disease followed for 21 years by a single hospital in Japan. Eur J Pediatr. 2008.Google Scholar
  36. 36.
    Kansoy S, et al. Successful bone marrow transplantation in an 8-month-old patient with chronic granulomatous disease. Turk J Pediatr. 2006;48(3):253–5.PubMedGoogle Scholar
  37. 37.
    Schuetz C, et al. Successful unrelated bone marrow transplantation in a child with chronic granulomatous disease complicated by pulmonary and cerebral granuloma formation. Eur J Pediatr. 2007;166(8):785–8.PubMedCrossRefGoogle Scholar
  38. 38.
    Sastry J, et al. Allogeneic bone marrow transplantation with reduced intensity conditioning for chronic granulomatous disease complicated by invasive Aspergillus infection. Pediatr Blood Cancer. 2006;47(3):327–9.PubMedCrossRefGoogle Scholar
  39. 39.
    Gungor T, et al. Successful low toxicity hematopoietic stem cell transplantation for high-risk adult chronic granulomatous disease patients. Transplantation. 2005;79(11):1596–606.PubMedCrossRefGoogle Scholar
  40. 40.
    Leung T, et al. Bone marrow transplantation for chronic granulomatous disease: long-term follow-up and review of literature. Bone Marrow Transplant. 1999;24(5):567–70.PubMedCrossRefGoogle Scholar
  41. 41.
    Ho CM, et al. Successful bone marrow transplantation in a child with X-linked chronic granulomatous disease. Bone Marrow Transplant. 1996;18(1):213–15.PubMedGoogle Scholar
  42. 42.
    Hasegawa D, et al. Successful treatment of chronic granulomatous disease with fludarabine-based reduced-intensity conditioning and unrelated bone marrow transplantation. Int J Hematol. 2008;87(1):88–90.PubMedCrossRefGoogle Scholar
  43. 43.
    Parikh SH, et al. Correction of chronic granulomatous disease after second unrelated-donor umbilical cord blood transplantation. Pediatr Blood Cancer. 2007;49(7):982–4.PubMedCrossRefGoogle Scholar
  44. 44.
    Suzuki N, et al. Treatment of McLeod phenotype chronic granulomatous disease with reduced-intensity conditioning and unrelated-donor umbilical cord blood transplantation. Int J Hematol. 2007;85(1):70–2.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  1. 1.National Institutes of HealthBethesdaUSA
  2. 2.National Institutes of HealthBethesdaUSA

Personalised recommendations